


Customized Oncology and Immuno-Oncology Solutions

Advanced approaches for biomarker-driven oncology therapeutic development

Precision is the first CRO designed specifically to apply a biomarker-focused, precision medicine approach to oncology therapeutic development. Our end-to-end integration of assays, translational informatics, and full-scale trial execution, coupled with expertise in novel and adaptive trial methodologies, optimizes the entire oncology development pathway.

Selection of Assays and Services





Customized workflows generate rich biopsy data

Precision leverages integrated platform technologies and customized workflows to generate incredibly rich datasets and in-depth biomarker analyses.


- Analyze tumor microenvironment composition and architecture
- Determine predictive and prognostic biomarkers
- Patient enrollment stratification
- Monitor single-cell immune response via cell profiling


Probe "hot" vs "cold" tumors

Expertise in profiling tumors using immunohistochemistry and multiplexed immunofluorescence

Uniquely positioned to help researchers probe and understand tumors, Precision offers conventional IHC as well as multiplex immunofluorescence and immuno-oncology IF panels.

- Quantitative immunofluorescence using Vectra Polaris: 9-color multiplexing with real-time data; spatially resolved analysis with HALO software
- Multiplex IHC with central pathology
- FISH, ISH, next-generation sequencing






Maximize liquid biopsy biomarker information using CTC capture technology and downstream characterization

- ApoStream[®] proprietary cell separation and enrichment platform
- Capture concentrated CTCs without antibodies
- Use any downstream platform for analysis: extremely powerful biomarker platform when coupled with quantitative IF







Diverse solutions supporting studies from phases 1-3

- Cell-based phenotyping with flow cytometry up to 31 colors with standard and customized panels
- Multicolor ELISpot and Fluorospot
- Gene expression profiling NanoString, ddPCR, qPCR, NGS
- Functional assays RO, ICS, proliferation/ suppression
- Multiplex cytokine profiling MSD, Luminex, SIMOA, ELISA
- Extensive immunogenicity and bioanalytical testing for biologics

Instrumentation for research assays or assays performed under CLIA

Proprietary molecular phenotyping simplifies global logistics

- Epiontis ID: proprietary epigenetic marker-based phenotyping for immune monitoring
- Assays compatible with any sample type (blood, PBMCs, tissue) and any condition (fresh or frozen); no complex sample prep needed
- Low sample volume requirements


- Robust and repeatable assay independent of technician skill
- Ideal for large, multicenter studies or studies where sampling is a challenge



35 validated assays including T, B, NK, Treg, Tfh, and pDCs

O Multiomic Data Integration and Informatics

Seamless organization of multiomic data and rapid in-study analysis and insights





- Harmonize complex data types
- Generate AI-derived signatures across diverse multiomic data sets for complex biological insights
- Integrate biomarker and clinical data to enable data-informed trial decisions

Deep, specialized experience in oncology

Precision has conducted over 300 clinical trials across disease types and drug classes. Our team applies this experience in planning trial designs, formulating regulatory strategy, and conducting all aspects of your trial.

- Experienced oncology team spanning every resource level
- Deep engagement from seasoned oncology CRAs
- Acceleration of complex trials through real-time biomarker data analysis

20+ YEARS DEDICATED TO ONCOLOGY CLINICAL TRIALS

300+ ONCOLOGY CLINICAL TRIALS CONDUCTED


Oncology Site Network for predictable start-up and performance

Precision's Oncology Site Network (OSN) puts enrollment-ready sites at your fingertips, pairing site selection with an optimized activation process

- Well-vetted, prequalified oncology sites accelerate site selection
- Academic and community-based sites throughout North America, Europe, and Asia-Pacific

- Targeted start-up within 90 days
- Nursing and resource models to support patient-centric treatment
- Highly skilled in conducting phase 1 trials with challenging PK sampling and biopsy requirements





Download your digital copy



precisionformedicine.com



© 2022. All rights reserved. Rev. 06